UPDATE: Qiagen Q3 Revenues Climb 5 Percent
November 05, 2012
UPDATE: Qiagen Q3 Revenues Climb 5 Percent
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Qiagen Q4, 2012 Growth Driven Significantly by QiaSymphony Sales in MDx, Applied Markets
January 31, 2013 / PCR Insider - Qiagen Plans Mid-Year Launch of Clinical NGS Platform; Says Gene Panels will Complement RT-PCR Tests
January 9, 2013 / Clinical Sequencing News - Qiagen Expands Companion Dx Portfolio with Three Licensing Deals; Exceeds 2012 QiaSymphony Placement Target
January 7, 2013 / GenomeWeb Daily News - Q&A: Med Tech from St. Luke's Hospital on Boosting Efficiency in the Molecular Pathology Lab
December 6, 2012 / PCR Insider - Qiagen, Bayer Partner on Cancer Companion Dx
October 25, 2012 / GenomeWeb Daily News